

Patient Blood Management (PBM)

A New Perioperative Transfusion Concept

Hans Gombotz

Department of Anesthesiology and
Intensive Care, General Hospital Linz

Austria



Disclosure - Conflicts of Interest

In the past years I received honoraria and travel support for consulting and lecturing from

- Australian Red Cross Blood Service
- Austrian Federal Ministry of Health
- Abbott
- CSL Behring
- Fresenius Kabi
- Haemonetics
- Janssen-Cilag
- Novo Nordisk
- Ortho Biotech
- Pentapharm/TEM
- Vifor Pharma
- Western Australian Department of Health
- ...

What is patient blood management?

- PBM views a patient's own blood as a valuable and unique natural resource that should be conserved and managed appropriately.
- PBM employs a patient-specific **perioperative multidisciplinary, multimodal team approach** to optimising, conserving and managing patients own blood.
- PBM aims to identify patients at risk of transfusion and provide a managed plan aimed at **reducing or eliminating the need for allogeneic transfusion with an acceptable risk of anemia.**

Enter Keywords All Issues

[Advanced Search](#) [Saved Searches](#) [Recent Searches](#)

[Home](#) [Current Issue](#) [Previous Issues](#) [Published Ahead-of-Print](#) [Collections](#) [CME](#) [For Authors](#) [Journal Info](#)

[Home](#) > [December 2008 - Volume 109 - Issue 6](#) > **Patient Blood Management: The Pragmatic Solution for the Pro...**

[< Previous Article](#) | [Next Article >](#)

Anesthesiology:
December 2008 - Volume 109 - Issue 6 - pp 951-953
doi: 10.1097/ALN.0b013e31818e3d75
Editorial Views

Patient Blood Management: The Pragmatic Solution for the Problems with Blood Transfusions

Spahn, Donat R. M.D., F.R.C.A.; Moch, Holger M.D.; Hofmann, Axel M.E.; Isbister, James P. M.B., F.R.A.C.P.


EDITORIALS


New Blood, Old Blood, or No Blood?

John W. Adamson, M.D.

Patient blood management

Adamson J.W. New Engl J Med (2008) 358: 1225





Sixty-third World Health Assembly

Date: 17–21 May 2010

Location: Geneva, Switzerland

The Sixty-third session of the World Health Assembly took place in Geneva during 17–21 May 2010. At this session, the Health Assembly discussed a number of public health issues, including:



**WHA63.12 adopted
by resolution May 21, 2010:**

„Bearing in mind that **patient blood management means** that before surgery every reasonable measure should be taken to **optimize the patient’s own blood volume, to minimize the patient’s blood loss and to harness and optimize the patient-specific physiological tolerance of anaemia** following WHO’s guide for optimal clinical use (**three pillars of patient blood management**)“



United States



Sections ▾

Browse ▾

Search ▾

Policy ▾

Learn ▾

Blog

Search Articles



FEDERAL REGISTER

The Daily Journal of the United States Government

Notice

Meeting of the Advisory Committee on Blood Safety and Availability

A Notice by the Health and Human Services Department on 05/06/2011



On June 8, 2011, the Committee will be asked to review and comment on WHA 63.12 regarding the availability, safety and quality of blood products. http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_R12-en.pdf Specifically the Committee will be asked to review the current status of safe and rational use of blood products in patient blood management and assess the current status in the U.S.

Australia



About Us | Blood Sector Policy | Ensuring Supply | Blood Sector Risk Management | Appropriate Blood Use | Blood Sector Data | Factsheets

- [Patient Blood Management Guidelines Development](#)
- [Progress Updates](#)
- [Public Consultation](#)

PATIENT BLOOD MANAGEMENT GUIDELINE DEVELOPMENT

The review of the 2001 [NHMRC/ASBT Clinical Practice Guidelines for the Use of Blood Components](#) is being undertaken with funding and project management provided by the National Blood Authority (NBA) on behalf of all governments. The NBA has facilitated the formulation of a Steering Committee, Expert Working Group, and Clinical/Consumer Reference Groups.

NHMRC Guidelines Development:

- Module 1 - Critical Bleeding/Massive Transfusion
- Module 2 - Peri operative
- Module 3 - Medical
- Module 4 - Intensive Care
- Module 5 - Obstetric
- Module 6 - Paediatric/Neonates

<http://www.nba.gov.au/guidelines/review.html>

ent.

The Real World

Paradigm Shift



Blood transfusions improve healing...

MYTH BUSTED

Current, emerging evidence shows that patients who receive blood transfusions are at greater risk of transfusion associated adverse outcomes such as infection, kidney failure, lung injury or death.

A recent study on red cell transfusions and haemostatic inhibitors in critically ill patients¹ concluded that infection rate was higher in those patients transfused compared to those who weren't. Mortality and length of stay (intensive care unit and hospital) were significantly higher in transfused patients, even when controlled for these severity.

Transfused patients, even after adjusting for survival probability, had significantly:

- Higher nosocomial infection (NI) rates (14.3% vs 5.6%, P < .0001)
- Longer ICU LOS (8.2 vs 3.3 days; P < .0001)
- Longer hospital LOS (18.3 vs 9.9 days; P < .0001)
- Higher mortality rates (21.6% vs 10.2%; P < .0001)

A blood transfusion is a living tissue transplant. With any transplant the human body is innately primed to react to something foreign. The safety implications of this are significant. Remember - consider all the factors, not just Hb, before transfusing.

Hb < 70g/L
 Lower transfusion threshold
 Lower mortality
 Lower LOS
 Lower LOS
 Lower LOS

Consider
 Hb 70-100g/L
 Use this range to guide transfusion decisions
 Only transfuse if there are signs of anaemia
 If there are signs of anaemia, consider other options
 (e.g. iron, erythropoietin)

Stop
 Hb > 100g/L
 Not transfuse
 Not transfuse
 Not transfuse

For more information about appropriate transfusion practices go to:
www.cec.health.nsw.gov.au and www.transfusion.com.au

NSW HEALTH
 Australian Red Cross BLOOD SERVICES
 CLINICAL TRANSFUSION COMMISSION

Blood Myth #3

Autologous blood, (pre-donated) is risk free...

MYTH BUSTED

Pre-donated autologous transfusion is not risk free and there are a variety of adverse events associated with this practice.

Use of autologous blood still carries equal, if not greater, risk of bacterial contamination. There are three reasons for this:

- autologous donor cultures are generally more bacteria than allogeneic donor acceptance
- it is possible that autologous donor sampling, at the point of operation is less precise and rigorous
- the typically longer storage interval of autologous RBC units increases the opportunity for bacterial proliferation.

Complications of Autologous transfusion

- Blood wastage
- Errors and accidents
- Delayed reactions
- Bacteremia
- Volume overload

Autologous donations may cost the patient \$200 or more, per unit collected.

For more information about the risk of autologous transfusion go to:
www.cec.health.nsw.gov.au and www.transfusion.com.au

NSW HEALTH
 Australian Red Cross BLOOD SERVICES
 CLINICAL TRANSFUSION COMMISSION

Blood Myth #4

Blood, it's safer than it's ever been...

MYTH BUSTED

Bacterial contamination, incompatibility reaction and transfusion-related acute lung injury (TRALI) are still the most common and most immediately dangerous complications of blood transfusion.

SERIOUS RISKS

Non-Bacterial Risk	100,000 RBC units
Septic shock	1:1,000,000
Acute lung injury	1:1,000,000
TRALI	1:1,000,000
Transfusion associated graft-versus-host disease (T-GVHD)	1:1,000,000
Transfusion associated circulatory overload (TACO)	1:1,000,000
Transfusion associated haemolytic reaction (TAH)	1:1,000,000
Transfusion associated hyperkalemia (TAHK)	1:1,000,000
Transfusion associated hypocalcaemia (TAHC)	1:1,000,000
Transfusion associated hypothermia (TAHT)	1:1,000,000
Transfusion associated hypernatremia (TAHN)	1:1,000,000
Transfusion associated hypoxemia (TAHO)	1:1,000,000
Transfusion associated hyperoxemia (TAHO)	1:1,000,000
Transfusion associated hyperkalemia (TAHK)	1:1,000,000
Transfusion associated hypocalcaemia (TAHC)	1:1,000,000
Transfusion associated hypothermia (TAHT)	1:1,000,000
Transfusion associated hypernatremia (TAHN)	1:1,000,000
Transfusion associated hypoxemia (TAHO)	1:1,000,000
Transfusion associated hyperoxemia (TAHO)	1:1,000,000

Patients are often still concerned about the risk of hepatitis or HIV from blood transfusions. However recent ANSDS statistics show us that the risk of contracting transmissible viruses is a rare occurrence in Australia.

VIRAL RISKS

Current estimated viral risks for Australian blood supply²

Risk	100,000 RBC units
Hepatitis B	1:1,000,000
Hepatitis C	1:1,000,000
HIV	1:1,000,000
CMV	1:1,000,000
HTLV	1:1,000,000
Parvovirus B19	1:1,000,000
West Nile Virus	1:1,000,000
Chikungunya	1:1,000,000
Dengue	1:1,000,000
Zika	1:1,000,000

For more information about adverse reactions to blood transfusions go to:
www.cec.health.nsw.gov.au and www.transfusion.com.au

NSW HEALTH
 Australian Red Cross BLOOD SERVICES
 CLINICAL TRANSFUSION COMMISSION

Blood Myth #1

A blood transfusion will get my patient home sooner...

MYTH BUSTED

There is emerging evidence that patients transfused after surgery stay longer in hospital and have more infections following discharge.

The 'COST study'³ shows that RBC transfusions are independently associated with longer ICU and hospital length of stay and increased mortality. Overall there were more complications in the patient cohort and the number of RBC units transfused was an independent predictor of worse clinical outcomes.

Intensifying transfusion: The number of RBC units transfused was significantly associated with a corresponding increase in median ICU LOS of 2.1, 3.8 and 10.1 days, respectively, and an increase in median hospital LOS of 3.5, 6.7 and 16.0 days, respectively.

In addition, a 2006 study⁴ of blood transfusions during cardiac surgery concluded that there was:

- a dose-dependent relationship between reductions in functional recovery for the patient and an increase in the units of red blood cells transfused
- a statistically negative, dose-adjusted effect on health-related quality of life after cardiac surgery that extended well beyond in-hospitalisation.

A blood transfusion is a living tissue transplant. With any transplant the human body is innately primed to react to something foreign. The safety implications of this are significant. Remember - consider all the factors, not just Hb, before transfusing.

For details on these studies and best practice guidelines on blood transfusions go to:
www.cec.health.nsw.gov.au and www.transfusion.com.au

NSW HEALTH
 Australian Red Cross BLOOD SERVICES
 CLINICAL TRANSFUSION COMMISSION

Blood Myth #2

Rationale for PBM

- Blood supply issues
- Cost of blood
- Transfusion practice variability
- **Transfusion safety and effectiveness**



Source of swine flu discovered!!

Pathogens – Costly Fear

The **AUSTRALIAN RED CROSS** discarded **33,600 liters** of donated **blood** as the result of fears that it was contaminated with **dengue** fever following an outbreak of the disease in northern Queensland in late 2009 and 2010, according to a report in the *Sunday Herald Sun*.

That loss ... accounted for about 7% of its overall blood supply.


A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care (Complications during ICU-stay)

	Restrictive (n=418)	Liberal (n=420)	p-value
Cardiac	55 (13.2%)	88 (21.0%)	<0.001
Pulmonary	106 (25.4%)	122 (29.0%)	0.22
Infectious	42 (10.0%)	50 (11.9%)	0.38
Gastrointestinal	13 (3.1%)	19 (4.5%)	0.28
Neurologic	25 (6.0%)	33 (7.9%)	0.28
Shock	67 (16%)	55 (13.1%)	0.23
Any	205 (49.0%)	228 (54.3%)	0.12

Table 2. Frequencies of Composite Infection and Ischemic Outcomes


Outcome	Not Transfused			Transfused		
	N	n	%	N	n	%
Infection*	3674	4842
Nadir hematocrit <21	52	1	1.9	982	120	12.2
Nadir hematocrit \geq 21 and <24	390	16	4.1	2164	243	11.2
Nadir hematocrit \geq 24 and <27	1176	42	3.6	1385	200	14.4
Nadir hematocrit \geq 27	2056	82	4.0	311	33	10.6
Ischemia†	3670	4848
Nadir hematocrit <21	52	1	1.9	982	132	13.4
Nadir hematocrit \geq 21 and <24	390	13	3.3	2167	307	14.2
Nadir hematocrit \geq 24 and <27	1175	40	3.4	1389	231	16.6
Nadir hematocrit \geq 27	2053	72	3.5	310	36	11.6

Intraoperative Transfusion of 1 U to 2 U Packed Red Blood Cells Is Associated with Increased 30-Day Mortality, Surgical-Site Infection, Pneumonia, and Sepsis in General Surgery Patients



Propensity and risk adjusted odds ratios (95% CI) for 30-day mortality and morbidity by level of intraoperative transfusion. Both morbidity and mortality risks were substantially increased after only 1 U RBC transfusion intraoperatively and continued to increase with increasing units. Circles, mortality; squares, morbidity.


Influence of Erythrocyte Transfusion on the Risk of Acute Kidney Injury after Cardiac Surgery Differs in Anemic and Nonanemic Patients



Rationale for PBM

- Blood supply issues
- Cost of blood
- **Transfusion practice variability**
- Transfusion safety and effectiveness

Blood Collection and RBC Transfusions (per 1.000 population) - EU 2008




Council of Europe, Final Report: The collection, testing and use of blood and blood products in Europe 2008
EUROSTAT 2008


Centers – Both Evaluations

Centers 2004/5


Additional centers 2009/10




Pre-operative blood request




Prevalence of Preoperative Anemia




RBC Transfusion in Patients with Preoperative Anemia




Treatment of Preoperative Anemia



Percentage of Patients Transfused in Different Centers (HTEP)



Percentage of Patients Transfused in Different Centers (KTEP)



Rationale for PBM

- **Blood supply issues**
- Cost of blood
- Transfusion practice variability
- Transfusion safety and effectiveness

Impact of the Ageing Population on Blood Demand

584 TRANSFUSION Volume 50, March 2010

BLOOD DONORS AND BLOOD COLLECTION

ALI ET AL.







Fig. 2. RBC usage per capita by age in Finland 2002 to 2006. Current annual RBC usage in Finland is 50 units per 1000 inhabitants.

Implications of demographics on future blood supply: a population-based cross-sectional study




Absolute numbers in 2005 and projection for 2020

Rationale for PBM


- Blood supply issues
- **Cost of blood**
- Transfusion practice variability
- Transfusion safety and effectiveness

Blood Safety Measures - Another Cost Driver

**America's Blood Centers
Safety Measures and Median Red Cell Service Fees in Current Dollars
1985 - 2009**



Activity Based Cost of Transfusion from a Provider's Perspective



Shander A, Hofmann A, Ozawa S, Theusinger O, Gombotz H, Spahn D.
Activity-Based Costs of Blood Transfusions in Surgical Patients at Four Hospitals. *Transfusion* Vol. 50, April 2010

Cost of transfusion outcome

Frequency and outcomes of blood products transfusion across procedures and clinical conditions warranting inpatient care: an analysis of the 2004 healthcare cost and utilization project nationwide inpatient sample database.

- Retrospective cohort study of all hospitalisations in the US in 2004 (n=38.66 million) to assess in-hospital outcomes associated with blood transfusion.
- 5.8% (2.33 million) transfused
- After adjustment for age, gender, comorbidities, admission type or DRG transfusion associated with:
 - 1.7 increased odds of death (P<0.0001)
 - 1.9 increased odds of infection (P<0.0001)
 - 2.5 days longer LOS
 - \$17,194 higher charges (P<0.0001)

→ \$40.1 billion more charges for txed pts!

Implementing Patient Blood Management



Clinician's
Transfusion-Trigger Hb

Pre-op Hb
Patient 1

Expected
Nadir Hb
Patient 1

Blood loss
1,800ml

**Scenario 1 –
Patient
treated
w/o PBM**

0 2,0 4,0 6,0 8,0 10,0 12,0 14,0 Hb g/dL



Clinician's
Transfusion-Trigger Hb

Pre-op Hb
Patient 1

Expected
Nadir Hb
Patient 1

Blood loss
1,800ml



**Scenario 2 –
Patient
treated
w/ PBM**

1st Pillar

**Optimise
haemo-
poiesis**

- Fe
- B₁₂
- Folic Acid
- ESAs

0 2,0 4,0 6,0 8,0 10,0 12,0 14,0 Hb g/dL



Clinician's
Transfusion-Trigger Hb

Pre-op Hb
Patient 1



Expected
Nadir Hb
Patient 1

Blood
1,800

Blood loss
1,000ml

2nd Pillar

**Minimise
blood loss
& bleeding**

- Meticulous surgical hemostasis
- Topical hemostatic agents
- Systemic hemostatic agents
- Anesthesiological techniques
- Normothermia
- Induced hypotension
- etc.

**Scenario 2 –
Patient
treated
w/ PBM**

0 2,0 4,0 6,0 8,0 10,0 12,0 14,0 Hb g/dL



Clinician's
Transfusion-Trigger Hb

Pre-op Hb
Patient 1

Expected
Nadir Hb
Patient 1

Blood loss
1,000ml

**Scenario 2 –
Patient
treated
w/ PBM**

3rd Pillar

**Harness &
optimise
physio-
logical
tolerance
of anaemia**

- Keep pt. normovolemic
- FiO₂ 100%
- Minimising metabolic demand


0 2,0 4,0 6,0 8,0 10,0 12,0 14,0 Hb g/dL

Components of PBM

- Evaluation of the actual blood usage (data management)
- Optimising blood ordering schedules
- Increasing tolerance of anemia
- 3 pillar strategy
 - Optimising preoperative red cell mass
 - Minimising perioperative blood loss
 - Reducing transfusion trigger

Data Management

Single RBC unit txns vs total units txd



Example from EMMC USA

MSBOS


Maximum Blood Ordering Schedule

Authors	Type of surgery	CTR before	CTR after
Rogers et al. 2006	Orthopedics	3.21 : 1	1.62 : 1
Mehra et al. 2004	Knee replacement	4.90 : 1	1.70 : 1
Foley et al. 2003	Gynecology	2.25 : 1	1.71 : 1
Richardson et al. 1998	Various	1.80 : 1	1.80 : 1

1.7: 1 = reduction of€

Components of PBM

- ✓ Evaluation of the actual blood usage (data management)
- ✓ Optimising blood ordering schedules
- ✓ Increasing tolerance of anemia
- **3 pillar strategy**
 - Optimising preoperative red cell mass
 - Minimising perioperative blood loss
 - Reducing transfusion trigger



1st Pillar

Optimise patient's own red cell mass

Preoperative

- Detect anaemia
- Identify underlying disorder(s) causing anaemia
- Manage disorder(s)
- Refer for further evaluation if necessary
- Treat iron deficiency/anaemia of chronic disease/iron-restricted erythropoiesis
- Note: Anaemia is a contraindication for elective surgery

Intraoperative

- Timing surgery with haematological optimisation

Postoperative

- Stimulate erythropoiesis
- Be aware of drug interactions that can increase anaemia

2nd Pillar

Minimise blood loss

- Identify and manage bleeding risk
- Minimising iatrogenic blood loss
- Procedure planning and rehearsal
- Preoperative autologous blood donation (in selected cases or when patient choice)
- Other

- Meticulous haemostasis and surgical techniques
- Blood-sparing surgical techniques
- Anaesthetic blood conserving strategies
- Autologous blood options
- Pharmacological/haemostatic agents

- Vigilant monitoring and management of post-operative bleeding
- Avoid secondary haemorrhage
- Rapid warming / maintain normothermia (unless hypothermia specifically indicated)
- Autologous blood salvage
- Minimising iatrogenic blood loss
- Haemostasis/anticoagulation management
- Prophylaxis of upper GI haemorrhage
- Avoid/treat infections promptly
- Be aware of adverse effects of medication

3rd Pillar

Harness & optimise physiological tolerance of anaemia

- Assess/optimize patient's physiological reserve and risk factors
- Compare estimated blood loss with patient-specific tolerable blood loss
- Formulate patient-specific management plan using appropriate blood conservation modalities to minimise blood loss, optimise red cell mass and manage anaemia
- Restrictive transfusion strategies

- Optimise cardiac output
- Optimise ventilation and oxygenation
- Restrictive transfusion strategies

- Optimise tolerance of anaemia
- Maximise oxygen delivery
- Minimise oxygen consumption
- Avoid/treat infections promptly
- Restrictive transfusion strategies

1st Pillar

Optimise patient's own red cell mass

Preoperative

- Detect anaemia
- Identify underlying disorder(s) causing anaemia
- Manage disorder(s)
- Refer for further evaluation if necessary
- Treat iron deficiency/anaemia of chronic disease/iron-restricted erythropoiesis
- Note: Anaemia is a contraindication for elective surgery

Intraoperative

- Timing surgery with haematological optimisation

Postoperative

- Stimulate erythropoiesis
- Be aware of drug interactions that can increase anaemia

2nd Pillar

Minimise blood loss

- Identify and manage bleeding risk
- Minimising iatrogenic blood loss
- Procedure planning and rehearsal
- Preoperative autologous blood donation (in selected cases or when patient choice)
- Other

- Meticulous haemostasis and surgical techniques
- Blood-sparing surgical techniques
- Anaesthetic blood conserving strategies
- Autologous blood options
- Pharmacological/haemostatic agents

- Vigilant monitoring and management of post-operative bleeding
- Avoid secondary haemorrhage
- Rapid warming / maintain normothermia (unless hypothermia specifically indicated)
- Autologous blood salvage
- Minimising iatrogenic blood loss
- Haemostasis/anticoagulation management
- Prophylaxis of upper GI haemorrhage
- Avoid/treat infections promptly
- Be aware of adverse effects of medication

3rd Pillar

Harness & optimise physiological tolerance of anaemia

- Assess/optimize patient's physiological reserve and risk factors
- Compare estimated blood loss with patient-specific tolerable blood loss
- Formulate patient-specific management plan using appropriate blood conservation modalities to minimise blood loss, optimise red cell mass and manage anaemia
- Restrictive transfusion strategies

- Optimise cardiac output
- Optimise ventilation and oxygenation
- Restrictive transfusion strategies

- Optimise tolerance of anaemia
- Maximise oxygen delivery
- Minimise oxygen consumption
- Avoid/treat infections promptly
- Restrictive transfusion strategies

Patients for elective surgery should present at the preoperative ambulance as soon as a possible (4 weeks before their surgery).

Start preoperative phase

Primary examination

Indication?

Standards to minimize preoperative blood loss:

1. Minimizing diagnostic blood losses/microsampling
2. Minimizing interventional blood losses

Trauma surgery/emergency

Algorithm (3)

Surgery with postponed urgency

Algorithm (2)

Elective surgery

History of bleeding

Positive?

yes

Intake of coagulation inhibitors?

yes

Stop administration of inhibitors (occasionally antagonize inhibitors and control)

no

Coagulation test positive?

yes

Normalize hemostasis

no

no

no



Documentation for all hospital departments

Measurement of preop. Hct

Determination of lowest individually tolerable transfusion trigger (Hct)

Calculation of circulating preop. RBC volume (ml)

Meticulous multidisciplinary planning of operation in regard of multimodal blood conservation

Estimation of intraop. RBC loss (ml)

Transfusion Needs


Postop. Hct > trigger Hct?

PBM PLANNING


Prävalenz der (präoperativen) Anämie

Nach Grunderkrankung	
Diabetes	14 - 15 %
Herzinsuffizienz	10 - 80 %
Akuter Myokardinfarkt	6 - 18 %
Infektionen	bis zu 95%
Tumorerkrankungen	bis zu 77%
Autoimmunerkrankung	bis zu 71%
Nierenerkrankungen	bis zu 50%
COPD	23%
Präoperativ	
ASA I und ASA II	1 %
Knie- und Hüftoperation	20 - 35 %
Allgemeinchirurgische Eingriffe	bis zu 40 %
Colonchirurgie	25 - 70 %
Herz- und Gefäßoperationen	16 - 40 %

30-day mortality, by anaemia and risk factor status



30-day composite morbidity, by anaemia and risk factor status



Patient blood management is key before elective surgery



Writing in *The Lancet*, Khaled Musallam and colleagues address an important topic through their analysis of the American College of Surgeons' National Surgical Quality Improvement Program database;¹ namely, what is the prevalence of preoperative anaemia in patients undergoing major non-cardiac surgery and what are the implications? Moreover, by removal of data for allogeneic red-blood-cell transfusions in their analysis (and thus in the absence of treatment for anaemia) the independent and natural course of preoperative anaemia is shown. The main finding of their study² was that preoperative anaemia—even to a mild degree—was significantly and independently associated with increased postoperative morbidity and mortality. This association might be aggravated by concomitant perisurgical blood loss³ and (frequently unnecessary) allogeneic transfusions.³ I believe that Musallam and colleagues' findings could have an enormous effect on health-care systems worldwide because preoperative diagnosis and treatment of anaemia (apart from transfusions of red blood cells) has almost never been undertaken routinely before surgery.³

Anaemia is a serious but easily treatable condition. Treatment is less costly than is transfusion and would possibly improve outcomes, not only by increased tolerance of perioperative blood loss and avoidance of allogeneic transfusions but also through elimination of the risk of anaemia by maintaining increased physiological haemoglobin values throughout the perioperative period.⁴

Because of the nature of Musallam and colleagues' retrospective observational study,¹ the cause of anaemia was not assessed. However, about a third of patients with anaemia probably would have had nutritional deficiencies, a third probably would have had chronic disease, and a third would have had anaemia from an unknown cause.⁵ Moreover, diagnostic and interventional blood loss might have had an additional role in the rates of anaemia reported.

Because of the prevalence, treatability, and negative outcomes of preoperative anaemia, preservation and improvement of preoperative red-blood-cell mass is essential as one of the three pillars of the new patient blood management strategy,⁶ which lasts for the entire perioperative period and has a patient-specific perioperative multidisciplinary and multifaceted team approach.

Implementation of the patient blood management strategy not only reduces transfusion requirements but also improves postoperative outcome, at least in patients undergoing orthopaedic and cardiac surgery.^{2,8}

However, some drawbacks of preoperative anaemia treatment need to be considered. Diagnosis and treatment of preoperative anaemia is time consuming and therefore detection and assessment of anaemia should be undertaken close to 28 days before a scheduled surgery to enable adequate treatment.⁹ Furthermore, in case of unexplained anaemia a planned surgery with substantial predicted blood loss should be rescheduled.⁹ In some populations of patients, treatment with iron or erythropoiesis-stimulating drugs might be ineffective, have serious side-effects, and therefore not be indicated.^{10,11} Moreover, at least in patients with chronic disease, anaemia might be regarded as an adaptive mechanism. For such patients, treatment of mild-to-moderate anaemia with iron or erythropoiesis-stimulating drugs might increase mortality despite an improvement in functional capacity and wellbeing.¹²

Nonetheless, Musallam and colleagues' study¹ strongly suggests that implementation of treatment of anaemia as part of a universal patient blood management strategy should become standard of care in patients undergoing elective surgical procedures, particularly in those where substantial blood loss is expected. However, additional studies are urgently needed to secure the efficacy and safety of preoperative treatment of anaemia.

Published Online
October 6, 2011
DOI:10.1016/S0140-6736(11)61552-3

See Online/Articles
DOI:10.1016/S0140-6736(11)61381-0




Gombotz H: www.thelancet.com

Published online October 6, 2011 DOI:10.1016/xxxx

Invited comment

Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines.



1st Pillar

Optimise patient's own red cell mass

- Detect anaemia
- Identify underlying disorder(s) causing anaemia
- Manage disorder(s)
- Refer for further evaluation if necessary
- Treat iron deficiency/anaemia of chronic disease/iron-restricted erythropoiesis
- Note: Anaemia is a contraindication for elective surgery

- Timing surgery with haematological optimisation

- Stimulate erythropoiesis
- Be aware of drug interactions that can increase anaemia

2nd Pillar

Minimise blood loss

- Identify and manage bleeding risk
- Minimising iatrogenic blood loss
- Procedure planning and rehearsal
- Preoperative autologous blood donation (in selected cases or when patient choice)
- Other

- Meticulous haemostasis and surgical techniques
- Blood-sparing surgical techniques
- Anaesthetic blood conserving strategies
- Autologous blood options
- Pharmacological/haemostatic agents

- Vigilant monitoring and management of post-operative bleeding
- Avoid secondary haemorrhage
- Rapid warming / maintain normothermia (unless hypothermia specifically indicated)
- Autologous blood salvage
- Minimising iatrogenic blood loss
- Haemostasis/anticoagulation management
- Prophylaxis of upper GI haemorrhage
- Avoid/treat infections promptly
- Be aware of adverse effects of medication

3rd Pillar

Harness & optimise physiological tolerance of anaemia

- Assess/optimize patient's physiological reserve and risk factors
- Compare estimated blood loss with patient-specific tolerable blood loss
- Formulate patient-specific management plan using appropriate blood conservation modalities to minimise blood loss, optimise red cell mass and manage anaemia
- Restrictive transfusion strategies

- Optimise cardiac output
- Optimise ventilation and oxygenation
- Restrictive transfusion strategies

- Optimise tolerance of anaemia
- Maximise oxygen delivery
- Minimise oxygen consumption
- Avoid/treat infections promptly
- Restrictive transfusion strategies

Preoperative

Intraoperative

Postoperative

General standards and advanced measures

General standards to minimize **intra- und postoperative** blood loss:

1. Maintaining normovolemia
2. Maintaining normothermia
3. Minimizing diagnostic blood losses/microsampling
4. Exact intra- und postoperative management of hemostasis
5. Accepting low transfusion trigger

Advanced anesthesiological measures to minimize **intraoperative** blood loss:

1. Controlled hypotension (contraindikation!)
2. Regional anesthesia


Modify Surgery??

Surgical standards to minimize blood loss:

1. Using surgical standards
2. Using anatomically sound and atraumatic surgical techniques
3. Applying meticulous surgical hemostasis


Advanced surgical measures to minimize blood loss:

1. Using optimal surgical instruments depending on indication (laser, ultrasonic scalpel, Dissectors, etc.)
2. Using local ischemia during certain sequences of operation (clamping vessels of high blood volume)





Approximate contributions of selected PBM modalities in the surgical patient	Number of RBC saved	units
Perioperative		
Harnessing patient's tolerance of anaemia (restrictive transfusion trigger)	1-2	¹⁴⁶
Restricted phlebotomy	1	¹²⁸
Pre-operative		
Optimisation of RBC mass (perioperative anaemia management)	2	^{184, 185}
Intra-operative		
Meticulous haemostasis & surgical technique	1 or more	¹⁸⁶
Acute normovolaemic haemodilution (ANH)	1 or more	^{89, 187}
Autologous cell salvage	1 or more	¹⁸⁸
Post-operative		
Autologous blood salvage	1	¹⁸⁹

Adapted with author consent from Shander A. Surgery without blood. Crit Care Med 2003 Dec;31(12 Suppl):S708-S714.



Up to 50% reduction of blood loss!!!

The influence of baseline hb concentration on tolerance of anemia in cardiac surgery



The relationship between maximum decrease in Hb concentration and adverse outcomes was independently associated with increased risk!!

1st Pillar

Optimise patient's own red cell mass

- Detect anaemia
- Identify underlying disorder(s) causing anaemia
- Manage disorder(s)
- Refer for further evaluation if necessary
- Treat iron deficiency/anaemia of chronic disease/iron-restricted erythropoiesis
- Note: Anaemia is a contraindication for elective surgery

- Timing surgery with haematological optimisation

- Stimulate erythropoiesis
- Be aware of drug interactions that can increase anaemia

2nd Pillar

Minimise blood loss

- Identify and manage bleeding risk
- Minimising iatrogenic blood loss
- Procedure planning and rehearsal
- Preoperative autologous blood donation (in selected cases or when patient choice)
- Other

- Meticulous haemostasis and surgical techniques
- Blood-sparing surgical techniques
- Anaesthetic blood conserving strategies
- Autologous blood options
- Pharmacological/haemostatic agents

- Vigilant monitoring and management of post-operative bleeding
- Avoid secondary haemorrhage
- Rapid warming / maintain normothermia (unless hypothermia specifically indicated)
- Autologous blood salvage
- Minimising iatrogenic blood loss
- Haemostasis/anticoagulation management
- Prophylaxis of upper GI haemorrhage
- Avoid/treat infections promptly
- Be aware of adverse effects of medication

3rd Pillar

Harness & optimise physiological tolerance of anaemia

- Assess/optimize patient's physiological reserve and risk factors
- Compare estimated blood loss with patient-specific tolerable blood loss
- Formulate patient-specific management plan using appropriate blood conservation modalities to minimise blood loss, optimise red cell mass and manage anaemia
- Restrictive transfusion strategies


- Optimise cardiac output
- Optimise ventilation and oxygenation
- Restrictive transfusion strategies

- Optimise tolerance of anaemia
- Maximise oxygen delivery
- Minimise oxygen consumption
- Avoid/treat infections promptly
- Restrictive transfusion strategies

Preoperative

Intraoperative

Postoperative



Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion

- Restrictive transfusion strategies reduced the risk of receiving a red blood cell (RBC) transfusion by a relative **42%**. This equates to an average absolute risk reduction (ARR) of 40%.
- The volume of RBCs transfused was reduced on average by 0.93 units.
- However, heterogeneity between these trials was statistically significant ($p < 0.00001$) for these outcomes.
- Mortality, rates of cardiac events, morbidity, and length of hospital stay were **unaffected**. Trials were of poor methodological quality.



ROBERT WOOD JOHNSON
MEDICAL SCHOOL

University of Medicine & Dentistry of New Jersey



Home

Information for Public

Information for
Health Professionals

Investigators
**PRINCIPAL
INVESTIGATORS**

Steering
Committee

Investigators

Major Institutions

Privacy Policy


Principal Investigators



Jeffrey L. Carson, MD
Principal Investigator and Study Chairman
Clinical Coordinating Center


Focus trial

AKH Linz Experience Primary Hip and Knee Replacement




Gombotz H. et al. Unpublished data.

Retrospektiver Vergleich bei anämischen PatientInnen mit einseitigem Hüftgelenkersatz



Unpublished data.

Retrospektiver Vergleich bei anämischen PatientInnen mit einseitigem Hüftgelenkersatz



Unpublished data.



Study evaluating PBM Outcomes

The Impact of Blood Conservation on Outcomes in Cardiac Surgery: Is It Safe and Effective?

David M. Moskowitz, MD, Jock N. McCullough, MD, Aryeh Shander, MD, James J. Klein, MD, Carol A. Bodian, DrPH, Richard S. Goldweit, MD, and M. Arisan Ergin, MD

Department of Anesthesiology, Critical Care Medicine, Hyperbaric Medicine and Pain Management, Department of Cardiothoracic Surgery, and Division of Cardiology, Department of Internal Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey; and Department of Anesthesiology, Division of Biostatistics, The Mount Sinai Hospital and Medical Center, New York, New York

Ann Thorac Surg 2010;90:451-9

propensity-score matched cohort of 500
pts from institutions without a PBMP

Isolated CABG includes elective & urgent and primary & redo procedures

The Impact of Blood Conservation on Outcomes in Cardiac Surgery: Is It Safe and Effective?

David M. Moskowitz, MD, Jock N. McCullough, MD, Aryeh Shander, MD, James J. Klein, MD, Carol A. Bodian, DrPH, Richard S. Goldweit, MD, and M. Arisan Ergin, MD

Department of Anesthesiology, Critical Care Medicine, Hyperbaric Medicine and Pain Management, Department of Cardiothoracic Surgery, and Division of Cardiology, Department of Internal Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey; and Department of Anesthesiology, Division of Biostatistics, The Mount Sinai Hospital and Medical Center, New York, New York

Ann Thorac Surg 2010;90:451-9

PBM strategies used:

1. Preop haemoglobin optimisation
2. Intraop ANH and Intra & Postop cell salvage
3. Meticulous surgical technique
4. Endovascular vein harvesting
5. Point-of-care coagulation testing
6. Targeted haemostatic therapy
7. Tolerance of perioperative anaemia (60 - 70 g/L depending on patient-specific physiology)

CABG Outcomes PBMP vs Non-PBMP

Outcome	PBMP cohort (n=586)	Non-PBMP cohort (n=586)	P-value
% Transfused	10.6%	42.5%	<0.0001
Mortality	0.8%	2.5%	0.02
Serious complication	11.1%	18.7%	0.0002

Moskowitz et al. The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective?
Ann Thorac Surg 2010;90:451-9